–––––––– –––––––– archives investing twitter
Brian Naughton | Mon 11 August 2014 | biotech | progress

Choosing a Vector

The second component of the vaccine is the vector (plasmid backbone). The one major criterion here is that the vector must be strongly and constitutively expressed in mammals.

Ideally, the vector is specifically designed for protein expression in mammals: i.e., it has a leader (signal) peptide, a Kozak sequence, a transcription termination signal, and optimizations to improve expression, such as enhancers.

Many vectors include myc epitopes and/or polyhistidine tags to enable you to recover the recombinant protein. With a DNA vaccine, we are not attempting to harvest the recombinant protein so this stuff is unnecessary, and may even be detrimental.

I first looked around for a suitable BioBrick vector, but I could not find one. I found a reference to addgene.org that seemed promising, but the plasmids I found there were limited to non-commercial use.

Although I'd prefer not to use a commercial vector, there are a few that seemed promising.

  • Invitrogen/Life Technologies pSecTag2
  • clonTech pIRES: The main advantage of this vector is that it can express two proteins from one CMV promoter thanks to an IRES
  • NEB pMCP

Next Steps

I am still working on choosing a vector. I need to look more into BioBricks, DNA 2.0's Electra system, and commercial vectors. There may be some useful information in gene design software too (Teselagen, Benchling, Genome Compiler...)

Comment
Brian Naughton | Sun 10 August 2014 | biotech | progress

Protein Design

Like the Slovenian iGEM entry from 2008, I decided to use flagellin as my antigenic protein.

The Slovenian team were attempting to elicit a humoral response to H. pylori flagellin — a protein that normally evades the mammalian immune system — by creating a hybrid flagellin that is part E. coli and part H. pylori. This would then allow for the creation of a vaccine against H. pylori. At least half the world's population is infected with H. pylori, famously discovered as the cause of stomach ulcers.

Flagellin is about 400 amino acids long, which turns out to be helpful since it's still a little complex to synthesize anything longer than 2000 nucleotides. For example, IDT's gBlocks, which are very inexpensive and commonly used, max out at 2000 nucleotides. It's not particularly difficult to combine fragments to make longer genes, but it's also not off-the-shelf.

E. coli flagellin is highly immunogenic, as you might expect from a common and abundant bacterial protein. There's even a specific innate immune receptor, Toll-like receptor 5, that recognizes flagellins.

So as a short-ish protein that evokes a strong immune response, flagellin is a reasonable choice for my experiment.

Codon optimization

For most amino acids, there is more than one corresponding codon. These codons vary in their efficiency of translation, and different organisms prefer different codons. The difference in the total amount of protein you get can be vast, so to maximize expression of my protein, I need to choose my codons carefully. There are many tools to help with this problem, including tools from IDT, DNA 2.0 and GenScript.

Apart from choosing the most highly expressed codons for your organism, the major thing these methods do is avoid motifs that lead to unwanted secondary effects, such as restriction sites, rho-independent termination or internal translation (IRES).

Next steps

It seems like it should be obvious, but I am still unsure which restriction sites I need to avoid in my protein sequence. E. coli methylates its genome to protect itself from self-cleaving and plasmid DNA is also apparently methylated, so the plasmid should be safe from E. coli restriction enzymes. However, I don't know which restriction enzyme will be used to clone my protein into its vector, so for now I am assuming I need to avoid any restriction sites contained in the multiple cloning site (MCS) of the vector.

Comment
Brian Naughton | Sat 09 August 2014 | biotech | progress

LaTex

I started a LaTex document to describe my first DNA vaccine experiment in detail. It may also potentially be usable as part of an SBIR grant. My hope is that the LaTex document will be a more formal summary of information written up for this blog.

Comment
Brian Naughton | Fri 08 August 2014 | biotech | progress

Progress report

Read More

Boolean Biotech © Brian Naughton Powered by Pelican and Twitter Bootstrap. Icons by Font Awesome and Font Awesome More